“showed a trend”

For the prime movers, the lateral gastrocnemius (LG) showed a trend toward less activity in the VL pedals than the LAT pedals, with an 8.4 ± 4.5% lower activation (mean ± SE; p = .080).

Hand grip strength test showed a trend to improve in Active-tDCS group (χ2(3) = 6.704, p = 0.08; Sham-tDCS: χ2(3) = 2.526, p = 0.47).

However, the subgroup analyses showed a trend for a treatment benefit in participants with more impaired pretreatment HCVA ( P = 0.08).

As regards physical activity, inconsistencies between parents and child-care staff with regard to promoting inactivity showed a trend for being associated with less MVPA (β = -.26, p = .08), as well as for a lower CPM (β = -.18, p = .099).

Japanese patients showed a trend towards fewer T2W-lesions (median 50 vs. 65, p = 0.08) and significantly lower frequencies of cerebellar and parietal lobe lesions ( p = 0.02 for both) than Caucasian patients.

The ANOVA on d’ showed a trend for the effect of emotion condition, F (2, 62) = 2.60, p = .08, η p 2 = .08.

Age- and sex-adjusted analysis for patients ≥10 years showed a trend towards increased risk of relapse for overweight/obese patients (HR = 2.89, 95% CI = 0.89–9.36, p =0.08) that was not evident among children<10 years (HR = 0.52, 95% CI = 0.08–3.54, p =0.49).

The use of emergency chemotherapy in ICU, although not statistically significant, showed a trend toward better survival (25 vs 12%, p = 0.080).

5 , the HIPP mice mastered the task also, but showed a trend towards longer acquisition times (p = 0.08), possibly reflecting this cognitive complication. 4.5.

The CAR T-cell+SCT group showed a trend toward higher complete remission (odds ratio [OR], 2.74; 95% confidence interval [CI], 0.88–8.54; P = 0.08; I 2 =57%; evidence, very low); lower mortality (OR, 0.58; 95% CI, 0.27–1.27; P =0.17; I 2 =0%; evidence, low), and decreased relapse (OR, 0.18; 95% CI, 0.06–0.56; P =0.003; I 2 =41%; evidence, low) rates than those who did not proceed to SCT.

Cognitive control Increased cognitive control showed a trend-level association with decreased connectivity of Component 1, Bilateral PCC with CCN ( r = −0.21, p = 0.08, 95% CI [−0.42, 0.03]).

showed a trend towards improvement in OS (7.1 versus 6.2 months, p = 0.08) and 12-month progression-free survival (PFS) (13.9 versus 8.4%, p = 0.004) with the use of gemcitabine plus capecitabine [ 9 ].

Two RCTs showed similar efficacy between EBL and EVO for treating GOV1 bleeding [ 201 , 231 ], another RCT showed a trend toward higher hemostasis rate in the EVO group compared to the EBL group (85% vs. 43%, P =0.08) [ 44 ].

Moreover, IL-4 treatment showed a trend ( p = 0.080) toward an increase in TG2 protein level (Fig. 1 e).

Regarding pathogen type, gram-negative infections showed a trend towards lower mortality (OR 0.53, 95% CI 0.27-1.04, p=0.08), though not statistically significant.

FSHD2 patients showed a trend to express more ACVRIIB than FSHD1 (+120%, p = 0.08).

One RCT showed a trend toward a decreased risk of low birth weight infants (6.6% GPC vs 12.5% control; p = 0.08; [ 32 ] while another showed no difference except in the subgroup that attended at least half of GPC visits (5.2% GPC vs 10.7% Control; p < 0.05; [ 8 ]).

These TPJ-dmPFC connectivity beta weights differed significantly between the disgust and neutral conditions in the left hemisphere (t 18 = 3.54, p = 0.002), and showed a trend to significance in the right (t 18 = 1.82, p = 0.08) (Fig. 6B,C ).

RMG showed a trend to be lower in LP compared to NP (p<0.08) at PND 10 and 12.

We observed that CA showed a trend (p = 0.08) towards decreased IFN γ mRNA expression.

Working Memory (SWM) Patients on modafinil showed a trend for fewer errors overall on the SWM task ( F = 3.023, p = .08, η p 2 = .05).

The other tested matrix-metalloproteinase MMP9 also showed a trend between these two groups, 0.39 ± 0.21 versus 1.14 ± 0.34 respectively, p < 0.08.

Doxorubicin Treatment Decreased the Cardiac Content of the Metabolic Regulator AMP-Activated Protein Kinase (AMPK), and Increased the Cardiac Content of Electron Transfer Flavoprotein-Ubiquinone Oxidoreductase (ETF-QO) One Week after Exposure The content of glucose transporter GLUT4 (GLUT4), which allows the import of glucose into cardiac cells [ 20 ], showed a trend to be decreased in the DOX1 group compared to CTRL1 ( p = 0.08, Figure 3 ), probably indicating a reduced uptake of glucose.

Also, APOBEC3B mRNA levels measured in distant metastases ( N = 35) showed a trend towards higher expression when compared to regional lymph node metastases ( N = 20) of unmatched cases (Mann-Whitney U test P = 0.08, Fig 2A ).

Both edoxaban doses demonstrated noninferiority to VKA in reducing the risk of stroke or SE in the primary analysis, including patients in the intent-to-treat population who received study drug during the treatment period (annual rates of 1.61%, 1.18%, and 1.50% for low-dose edoxaban, high-dose edoxaban, and warfarin, respectively); high-dose edoxaban showed a trend toward better efficacy vs warfarin in a prespecified superiority analysis of the intent-to-treat population during the entire study period (1.57% vs 1.80%; P =0.08). 29 In Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE), 18,201 patients (mean CHADS 2 score 2.1; median age 70 years) were randomized to apixaban 5 mg twice daily (2.5 mg doses were used in patients with two or more of the following: age ≥80 years, body weight ≤60 kg, or serum creatinine level ≥1.5 mg/dL) or warfarin.